Intellia Therapeutics Inc
NTLA
Market Cap$1.11B
Close$
$-5.18
148.2% downside
Current Fair Value
148.2% downsideOvervalued by 148.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.11 Billion |
|---|---|
| Enterprise Value | $1.13 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-5.25 |
| Beta | 2.13 |
| Outstanding Shares | 103,500,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.11 |
|---|---|
| PEG | -32.94 |
| Price to Sales | - |
| Price to Book Ratio | 1.53 |
| Enterprise Value to Revenue | 24.7 |
| Enterprise Value to EBIT | -2.13 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Intellia Therapeutics Inc
211 employees
CEO: John Leonard Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Th...